Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MAIA Biotechnology, Inc. Common Stock (NY: MAIA )

1.550 -0.030 (-1.90%)
Official Closing Price Updated: 4:10 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 38,306
Open 1.590
Bid (Size) 1.500 (1)
Ask (Size) 1.630 (1)
Prev. Close 1.580
Today's Range 1.550 - 1.630
52wk Range 1.290 - 5.990
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire

Performance

YTD
-25.84%
-25.84%
1 Month
-13.89%
-13.89%
3 Month
-22.89%
-22.89%
6 Month
-52.31%
-52.31%
1 Year
+15.66%
+15.66%

More News

Read More
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Private Placement of $2,715,000
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Present at Biotech Showcase 2025
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Private Placement of Approximately $950,000
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces $2.44 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
Via News Direct
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer
From MAIA Biotechnology
Via Business Wire
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024
Via InvestorPlace
MAIA Biotechnology (MAIA) is one of the earliest pioneers of telomere targeting as a therapeutic strategy
Via AB Newswire
Exposures Product Safety
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
Via Benzinga
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
From MAIA Biotechnology, Inc.
Via Business Wire
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
Via AB Newswire
Exposures COVID-19 Product Safety
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.